AI's role in strategic pharma decision-making: New industry insights

Cover Image

This research brief examines pharmaceutical leaders' risk assessment and strategic decision-making, emphasizing artificial intelligence (AI). Surveying over 100 management professionals, findings reveal:

  • Main challenges are data availability, subjectivity, and non-standardized risk assessment processes
  • While traditional methods like historical analysis are common, AI is underused
  • Decision-makers prioritize outcomes data over KOL assessments
  • A mere 25% employ AI in portfolio decisions, suggesting a significant opportunity

The study suggests AI, like Intelligencia's Portfolio Optimizer, could enhance objectivity in pharma risk assessment. The full brief offers more insights.

Vendor:
Intelligencia.ai
Posted:
Aug 28, 2024
Published:
Aug 29, 2024
Format:
HTML
Type:
Research Content
Already a Bitpipe member? Log in here

Download this Research Content!